Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AHCT intensification + daratumumab + lenalidomide
- Development stage
- Phase 3
- Lead developer
- University of Alabama at Birmingham
- Modality
- Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous, Oral, Parenteral
01
Overview
AHCT intensification + daratumumab + lenalidomide is a combination treatment regimen evaluated in the MASTER-2 trial (NCT05231629) for patients with newly diagnosed multiple myeloma (NDMM) who are minimal residual disease (MRD) positive. The regimen utilizes autologous hematopoietic cell transplantation (AHCT) as an intensification strategy, followed by consolidation and maintenance with daratumumab and lenalidomide. Daratumumab is a human IgG1κ monoclonal antibody that targets CD38, a protein highly expressed on myeloma cells, inducing cell death through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). Lenalidomide is an immunomodulatory drug (IMiD) that binds to cereblon, part of the E3 ubiquitin ligase complex, leading to the degradation of transcription factors Ikaros and Aiolos, which results in anti-proliferative and pro-apoptotic effects in myeloma cells while enhancing T-cell and NK-cell activity.
- Brand names
- Darzalex + Revlimid
- Other names
- AHCT + daratumumab + lenalidomideAHCT + Dara-Rautologous hematopoietic cell transplantation + daratumumab + lenalidomide
02
Targets
CD38 (Cluster of Differentiation 38)CRBN (Cereblon)DNA
Beyond the preview
Go deeper on AHCT intensification + daratumumab + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AHCT intensification + daratumumab + lenalidomide.